Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19950759 | 0.87 | ALDH1A1 (0.65) | TDP1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL10949671 | 0.84 | MEN1 (0.68) | ALDH1A1MEN1KMT2AMAPTPDE7A | |
| SCHEMBL21633970 | 0.83 | PTGS2 (0.48) | ALDH1A1MEN1KMT2AMAPTPDE7A | |
| SCHEMBL177792 | 0.80 | HSPB1 (0.59) | ALDH1A1MEN1KMT2AMAPTPTGS2 | |
| SCHEMBL11094289 | 0.80 | EPAS1 (0.51) | ALDH1A1MEN1KMT2AMAPTPDE7A | |
| SCHEMBL11296547 | 0.80 | TDP1 (0.73) | TDP1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL5088269 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2AMAPTPDE7A | |
| SCHEMBL27739212 | 0.78 | MEN1 (0.57) | TDP1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL27705527 | 0.75 | ALDH1A1 (0.51) | TDP1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL15067760 | 0.75 | SMN1; SMN2 (0.66) | KMT2APTGS2CYP3A4SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638036-B1 | COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO LTD (CN) | 2017-08-16 | — | — | EP | disclosed |
| US-9409900-B2 | Compound for increasing kinase active and application thereof | FUJIAN HAIXI PHARMACEUTICALS, INC. (CN) | 2016-08-09 | — | — | US | disclosed |
| US-9409900-B2 | Compound for increasing kinase active and application thereof | FUJIAN HAIXI PHARMACEUTICALS, INC. (CN) | 2016-08-09 | — | — | US | disclosed |
| US-20130225587-A1 | COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF | ZHEJIANG BETA PHARMA INCORPORATION (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20130225587-A1 | COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF | ZHEJIANG BETA PHARMA INCORPORATION (CN) | 2013-08-29 | — | — | US | disclosed |
| WO-2012062210-A1 | COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF | ZHEJIANG BETA PHARMA INC. (CN) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225587-A1 | COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF | MAP3K7, MAP3K1, MAP3K6 | TDP1 3175/4885ALDH1A1 2216/4885MEN1 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.